AZD8330

for treatment of patients with advanced malignancies

Also Known As:

2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; ARRY-424704; ARRY-704

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - AZD8330: 6

Experts

1.	He, Shuang-Li: 1 article (11/2018)
2.	Liang, Xue: 1 article (11/2018)
3.	Ma, Jie: 1 article (11/2018)
4.	Wang, Jin: 1 article (11/2018)
5.	Wang, Yan-Ru: 1 article (11/2018)
6.	Xu, Li-Hua: 1 article (11/2018)
7.	Xu, Yu-Lin: 1 article (11/2018)
8.	Yu, Tao: 1 article (11/2018)
9.	Zhang, Xiao-Jing: 1 article (11/2018)
10.	Dong, Lihua: 1 article (02/2015)

Related Diseases

1.	Inflammation (Inflammations) 12/01/2023 - "Given that inflammation is a primary causative factor in OA, it is posited that AZD8330 might exhibit superior efficacy in OA management. " 12/01/2023 - "Our study provides compelling evidence attesting to the capacity of AZD8330 in managing inflammation within the realm of OA treatment. " 12/01/2023 - "Our investigation delineates the role of AZD8330 in the regulation of inflammation in the context of OA treatment. "
2.	Neoplasms (Cancer) 05/01/2013 - "This phase I study defined the maximum tolerated dose (MTD) and assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8330 in patients with advanced malignancies. " 05/01/2013 - "A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies." 05/01/2013 - "Patients with refractory cancer or cancer with no standard therapy received either once-daily (OD) or twice-daily (BID) oral AZD8330 on day 1 followed by a 7-day washout period and continuous dosing from day 8. The starting dose was 0.5 mg with dose escalations in subsequent cohorts until a non-tolerated dose was reached. " 04/01/2014 - "This paper reviews the translational evidence in favor of MEK inhibitors in cancer, their role in gynecologic malignancies, and details regarding the status of the fourteen MEK inhibitors currently being clinically tested: trametinib, selumetinib, pimasertib, refametinib, PD-0325901, MEK162, TAK733, RO5126766, WX-554, RO4987655, cobimetinib, AZD8330, MSC2015103B, and ARRY-300."
3.	Osteoarthritis 12/01/2023 - "Consequently, the utilization of AZD8330 may hold potential in the prophylaxis of osteoarthritis. " 12/01/2023 - "This study lends credence to the notion that AZD8330 may be a promising contender for osteoarthritis therapy. " 12/01/2023 - "In this study, we investigated the potential of intraperitoneal injection of AZD8330 to retard the progression of osteoarthritis in a murine model with surgically induced medial meniscus destruction (DMM). " 12/01/2023 - "Upregulation of cIAP1 induced by AZD8330 alleviates osteoarthritis progression by inhibiting the RIP1-associated necrosis signaling pathway."
4.	Multiple Myeloma 10/01/2014 - "[Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells]." 10/01/2014 - "It is concluded that AZD8330 can efficiently inhibit the proliferation of NCI-H929 and IM9 cell lines, and induce apoptosis, suggesting that the AZD8330 may be a potential chemotherapeutic candidate for multiple myeloma therapy. " 10/01/2014 - "This study was aimed to investigate the effect of MEK inhibitor AZD8330 on proliferation and apoptosis of multiple myeloma IM9 and NCI-H929 cell lines and its possible mechanism. " 10/01/2014 - "The Wester blot was used to detect the expression levels of cyclin D and cyclin E, and multiple myeloma cells were treated with 10, 100, 1000 and 2000 nmol/L of AZD8330, the AnnexinV/7-AAD double staining was used to analyse cell apoptosis and the Western blot was used to detect the expression level of caspase-3. "
5.	Carcinogenesis 11/01/2018 - "We found that AZD8330 significantly prevented TRIM65 overexpression-induced tumorigenesis. "

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	Cyclin D
3.	Caspase 3 (Caspase-3)
4.	Cyclin E
5.	binimetinib
6.	RO5126766
7.	cobimetinib
8.	trametinib
9.	CH 4987655
10.	TAK 733

Related Therapies and Procedures

1.	Therapeutics
2.	Intraperitoneal Injections